This is the authors' abstract. We don't add key points for this paper.
This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
McComsey et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: